Omnicell Crecimiento futuro
Future controles de criterios 3/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Omnicell de 36.2% y 4.3% respectivamente, mientras que el BPA crecerá en un 35.7% al año.
Información clave
36.2%
Tasa de crecimiento de los beneficios
35.74%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Medical Equipment | 16.0% |
| Tasa de crecimiento de los ingresos | 4.3% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Good |
| Última actualización | 01 May 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Actualización del análisis • May 01
OMCL: New Product Cycle Will Reset Expectations And Support Higher Future Earnings Multiple
Analysts have reset their view on Omnicell, with the consolidated fair value estimate moving from $49.00 to $55.00. This reflects updated assumptions on discount rate, growth, margins and future P/E, alongside recent price target hikes and rating changes across the Street.Actualización del análisis • Apr 16
OMCL: New Product Cycle Will Drive Next Cabinet Super Cycle
Narrative Update on Omnicell Analysts now see a slightly lower blended price target for Omnicell, with recent moves spanning a $14 cut at one firm and a $10 increase at another. They are weighing a new product cycle against differing views on execution and risk.Actualización del análisis • Apr 01
OMCL: Cabinet Replacement Cycle Will Drive Future Super Cycle Repricing
Narrative Update on Omnicell The updated analyst price target for Omnicell has shifted by $14 as analysts balance recent upgrades tied to a new product cycle and cabinet replacement opportunity against a lower target from one firm, while keeping the model's fair value estimate steady at $49. Analyst Commentary Recent research on Omnicell presents a mixed picture, with some firms highlighting upside linked to a new product cycle and cabinet replacement opportunity, while more cautious voices are resetting expectations and price targets.Actualización del análisis • Mar 18
OMCL: Cabinet Replacement Cycle Will Drive Future Risk Reward Repricing
Analysts have trimmed the Omnicell fair value estimate from $50.00 to $49.00, reflecting slightly softer assumptions for revenue growth and profit margins, even as they factor in a higher future P/E multiple supported by recent upgrades tied to the new product cycle and cabinet refresh story. Analyst Commentary Recent Street research on Omnicell has been mixed, with some firms trimming price targets while others turn more constructive on the new product cycle and cabinet refresh opportunity.
Actualización del análisis • Mar 04
OMCL: Cabinet Replacement Cycle Will Drive Future Medication Management Upside
Analysts have adjusted their Omnicell price target by $14, reflecting mixed research that includes both target cuts and upgrades related to expectations around the new product cycle and potential cabinet replacement demand. Analyst Commentary Bullish Takeaways Bullish analysts see the new Titan XT cabinets as a key product that could support higher long term growth expectations if hospitals move ahead with planned cabinet replacements.Actualización del análisis • Feb 18
OMCL: Cabinet Refresh Cycle Will Support Future Medication Management Upside
Analysts have nudged their fair value estimate for Omnicell higher from $51.50 to about $57.43, citing updated views on its product cycle and cabinet refresh opportunity as reflected in recent research. Analyst Commentary Recent research coverage on Omnicell reflects a mix of optimism around the new product cycle and cabinet refresh, alongside some restraint on how quickly that opportunity may translate into value.Artículo de análisis • Feb 12
Why Investors Shouldn't Be Surprised By Omnicell, Inc.'s (NASDAQ:OMCL) 26% Share Price Plunge
The Omnicell, Inc. ( NASDAQ:OMCL ) share price has softened a substantial 26% over the previous 30 days, handing back...
Actualización del análisis • Feb 04
OMCL: Cabinet Replacement Cycle Could Drive Upside In Concentrated Market
Analysts have raised their fair value estimate for Omnicell to US$63 from US$55, citing updated assumptions for revenue growth, profit margins, and a lower future P/E multiple. This change is supported by recent positive research on the potential impact of the Titan XT cabinet cycle and competitive wins.Actualización del análisis • Jan 21
OMCL: Cabinet Replacement Cycle Will Shape Future Risk Reward Balance
Narrative Update on Omnicell The analyst price target for Omnicell has moved from $43 to $50 as analysts point to potential cabinet replacement demand and the Titan XT launch as key drivers for expected improvements in sales, earnings, and valuation assumptions. Analyst Commentary Recent research highlights a more constructive tone around Omnicell, with some analysts pointing to a potential cabinet replacement cycle and the Titan XT launch as key themes in their work.Actualización del análisis • Jan 06
OMCL: Future Medication Management Platform Rollout Will Support Balanced Risk Reward Profile
Analysts have lifted their price target on Omnicell from US$34 to US$43, pointing to updated assumptions for slightly lower discount rates, firmer revenue growth, improved profit margins, and a more moderate future P/E outlook. What's in the News Omnicell launched Omnicell Titan XT, an enterprise version of its automated dispensing systems designed to unify automation with its cloud-based OmniSphere medication management platform, aiming to create a connected, enterprise-wide medication management ecosystem across care areas.Actualización del análisis • Dec 18
OMCL: New Medication Management Platform Will Support Future Upside Potential
Analysts have raised their price target on Omnicell from approximately 47.33 dollars to 51.50 dollars. This change reflects slightly lower perceived risk, modestly stronger long term profit margins, and a higher expected future earnings multiple.Actualización del análisis • Dec 04
OMCL: Share Repurchases Will Support Future Upside Potential
Analysts have modestly raised their price target on Omnicell to approximately $47.33 per share, reflecting slightly lower perceived risk and stable, long-term growth and profitability expectations. What's in the News Updated fourth quarter 2025 revenue guidance to a range of $306 million to $316 million, signaling stable near term demand (company guidance).Actualización del análisis • Nov 20
OMCL: Share Repurchases And Executive Shifts Will Drive Future Upside
Analysts have revised their price target for Omnicell, lowering it modestly to $47.33 per share. This change reflects slight adjustments in key financial assumptions and uncertainty regarding future growth rates.Artículo de análisis • Nov 13
Improved Revenues Required Before Omnicell, Inc. (NASDAQ:OMCL) Stock's 25% Jump Looks Justified
Omnicell, Inc. ( NASDAQ:OMCL ) shareholders would be excited to see that the share price has had a great month, posting...Actualización del análisis • Nov 06
OMCL: Share Repurchases And Leadership Transition Will Strengthen Market Position
Omnicell's analyst price target has been raised from $44 to approximately $47.33 per share. Analysts cite improved outlooks for revenue growth, profit margins, and lower discount rates as reasons supporting the upward revision.Seeking Alpha • Jul 31
Omnicell Q2 Earnings: Market Ignoring The Segments
Summary Omnicell's service business is rapidly growing, now 22% of revenue, outpacing industry trends and supporting long-term upside. My updated DCF analysis yields a price target of $57.46, representing 93% upside, with Wall Street consensus trailing behind. The primary risk is the pace of transition from product to service revenue, but a strong backlog mitigates margin and cash flow concerns. Given robust service growth and healthy backlog, I maintain Omnicell at strong buy, seeing current volatility as a long-term buying opportunity. Read the full article on Seeking AlphaArtículo de análisis • Jul 16
Omnicell (NASDAQ:OMCL) May Have Issues Allocating Its Capital
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. One common...Artículo de análisis • Jun 28
Omnicell, Inc. (NASDAQ:OMCL) Shares Could Be 27% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Omnicell fair value estimate is US$40.16 Omnicell is estimated...Nuevo análisis • May 27
Near-shoring And Digitization Will Drive Stability Despite Tariff Challenges
Supply chain improvements and near-shoring are expected to offset cost pressures, while a shift to recurring SaaS and services enhances earnings stability and valuation potential.Artículo de análisis • May 14
It Looks Like Omnicell, Inc.'s (NASDAQ:OMCL) CEO May Expect Their Salary To Be Put Under The Microscope
Key Insights Omnicell's Annual General Meeting to take place on 21st of May CEO Randy Lipps' total compensation...Artículo de análisis • May 09
US$38.50: That's What Analysts Think Omnicell, Inc. (NASDAQ:OMCL) Is Worth After Its Latest Results
There's been a notable change in appetite for Omnicell, Inc. ( NASDAQ:OMCL ) shares in the week since its first-quarter...Artículo de análisis • Apr 07
Omnicell (NASDAQ:OMCL) Seems To Use Debt Rather Sparingly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Artículo de análisis • Mar 20
Is Now An Opportune Moment To Examine Omnicell, Inc. (NASDAQ:OMCL)?
Omnicell, Inc. ( NASDAQ:OMCL ), is not the largest company out there, but it received a lot of attention from a...Artículo de análisis • Feb 14
Why Omnicell's (NASDAQ:OMCL) Earnings Are Better Than They Seem
Despite posting healthy earnings, Omnicell, Inc.'s ( NASDAQ:OMCL ) stock has been quite weak. Our analysis suggests...Seeking Alpha • Feb 12
Omnicell Q4 Earnings: Ignore The Short-Term Noise
Summary Omnicell's Q4 2024 earnings showed strong service revenue growth, despite soft overall revenue guidance, highlighting the service business as the key value driver. My updated DCF analysis yields a price target of $64.05, representing a 54% upside, and I raise my rating from buy to strong buy. The service business has grown from 6% to 22% of revenue since 2020, outpacing industry growth and improving margins, indicating long-term value. Downside risks include the need to balance service growth with product decline, but the healthy backlog mitigates these concerns, presenting a buying opportunity. Read the full article on Seeking AlphaArtículo de análisis • Feb 09
Results: Omnicell, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
It's been a mediocre week for Omnicell, Inc. ( NASDAQ:OMCL ) shareholders, with the stock dropping 11% to US$40.16 in...Artículo de análisis • Jan 28
Omnicell, Inc. (NASDAQ:OMCL) Shares Could Be 26% Below Their Intrinsic Value Estimate
Key Insights Omnicell's estimated fair value is US$59.79 based on 2 Stage Free Cash Flow to Equity Omnicell's US$44.35...Artículo de análisis • Nov 27
Little Excitement Around Omnicell, Inc.'s (NASDAQ:OMCL) Revenues
With a price-to-sales (or "P/S") ratio of 2x Omnicell, Inc. ( NASDAQ:OMCL ) may be sending bullish signals at the...Artículo de análisis • Nov 02
Omnicell, Inc. Just Beat EPS By 43%: Here's What Analysts Think Will Happen Next
Shareholders will be ecstatic, with their stake up 23% over the past week following Omnicell, Inc. 's ( NASDAQ:OMCL...Seeking Alpha • Nov 01
Omnicell Q3 Earnings: Look At The Growth Segment
Summary Omnicell, Inc. is a pharmacy management provider working towards the goal of an autonomous pharmacy. Q3 earnings looked weak on the surface with revenue and EBITDA down, but results by business show a strong and growing service business. Omnicell has unique technology with strong market tailwinds that support long-term growth. Read the full article on Seeking AlphaArtículo de análisis • Oct 31
Is It Time To Consider Buying Omnicell, Inc. (NASDAQ:OMCL)?
Omnicell, Inc. ( NASDAQ:OMCL ), is not the largest company out there, but it led the NASDAQGS gainers with a relatively...Artículo de análisis • Oct 07
Is Omnicell (NASDAQ:OMCL) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2028 | 1,383 | 72 | 81 | N/A | 2 |
| 12/31/2027 | 1,315 | 46 | 72 | N/A | 8 |
| 12/31/2026 | 1,247 | 36 | 63 | N/A | 8 |
| 3/31/2026 | 1,225 | 20 | 95 | 156 | N/A |
| 12/31/2025 | 1,185 | 2 | 67 | 127 | N/A |
| 9/30/2025 | 1,178 | 20 | 94 | 153 | N/A |
| 6/30/2025 | 1,150 | 23 | 89 | 148 | N/A |
| 3/31/2025 | 1,136 | 21 | 108 | 164 | N/A |
| 12/31/2024 | 1,112 | 13 | 135 | 188 | N/A |
| 9/30/2024 | 1,064 | -18 | 118 | 170 | N/A |
| 6/30/2024 | 1,080 | -21 | 152 | 204 | N/A |
| 3/31/2024 | 1,103 | -21 | 165 | 218 | N/A |
| 12/31/2023 | 1,147 | -20 | 126 | 181 | N/A |
| 9/30/2023 | 1,186 | -34 | 165 | 225 | N/A |
| 6/30/2023 | 1,235 | -23 | 127 | 189 | N/A |
| 3/31/2023 | 1,268 | -18 | 48 | 107 | N/A |
| 12/31/2022 | 1,296 | 6 | 17 | 78 | N/A |
| 9/30/2022 | 1,309 | 48 | -5 | 55 | N/A |
| 6/30/2022 | 1,258 | 61 | 18 | 77 | N/A |
| 3/31/2022 | 1,199 | 72 | 98 | 158 | N/A |
| 12/31/2021 | 1,132 | 78 | 173 | 232 | N/A |
| 9/30/2021 | 1,070 | 80 | 195 | 249 | N/A |
| 6/30/2021 | 987 | 60 | 194 | 242 | N/A |
| 3/31/2021 | 914 | 35 | 164 | 218 | N/A |
| 12/31/2020 | 892 | 32 | 131 | 186 | N/A |
| 9/30/2020 | 891 | 38 | 86 | 144 | N/A |
| 6/30/2020 | 906 | 49 | 101 | 164 | N/A |
| 3/31/2020 | 924 | 69 | 85 | 144 | N/A |
| 12/31/2019 | 897 | 61 | N/A | 145 | N/A |
| 9/30/2019 | 860 | 54 | N/A | 158 | N/A |
| 6/30/2019 | 836 | 48 | N/A | 117 | N/A |
| 3/31/2019 | 807 | 38 | N/A | 112 | N/A |
| 12/31/2018 | 787 | 38 | N/A | 104 | N/A |
| 9/30/2018 | 772 | 54 | N/A | 61 | N/A |
| 6/30/2018 | 754 | 48 | N/A | 27 | N/A |
| 3/31/2018 | 747 | 44 | N/A | 16 | N/A |
| 12/31/2017 | 713 | 31 | N/A | 25 | N/A |
| 9/30/2017 | 688 | -1 | N/A | 45 | N/A |
| 6/30/2017 | 678 | -6 | N/A | 72 | N/A |
| 3/31/2017 | 670 | -9 | N/A | 56 | N/A |
| 12/31/2016 | 696 | 10 | N/A | 50 | N/A |
| 9/30/2016 | 651 | 8 | N/A | 54 | N/A |
| 6/30/2016 | 599 | 14 | N/A | 40 | N/A |
| 3/31/2016 | 539 | 24 | N/A | 44 | N/A |
| 12/31/2015 | 485 | 31 | N/A | 38 | N/A |
| 9/30/2015 | 476 | 32 | N/A | 37 | N/A |
| 6/30/2015 | 463 | 32 | N/A | 50 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (36.2% al año) de OMCL es superior a la tasa de ahorro (3.5%).
Beneficios vs. Mercado: Se prevé que los beneficios (36.2% al año) de OMCL crezcan más rápidamente que el mercado US (16.7% al año).
Beneficios de alto crecimiento: Se espera que los beneficios de OMCL crezcan significativamente en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (4.3% al año) de OMCL crezcan más despacio que el mercado de US (11.6% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 4.3% al año) de OMCL crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de OMCL se prevé que sea elevada dentro de 3 años.
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/11 16:18 |
| Precio de las acciones al final del día | 2026/05/11 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Omnicell, Inc. está cubierta por 20 analistas. 8 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Raymond Myers | Benchmark Company |
| William Sutherland | Benchmark Company |
| Zhilin Long | Berenberg |